Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data.
Share this article
Corporate
Score 65
Bullish
Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
Mar 27, 2026 01:15 UTC
PFE, XLV, IJK
Short term
Related Articles
Score 65
Bullish
New $1 Billion Airport Near Delhi to Test India’s Buildout Boom
Mar 28, 00:00
Score 75
Bearish
Fund With Anthropic Stake Slides in Post-Listing Reversal
Mar 27, 22:43
Score 55
Bullish
Kailera Therapeutics Files for US IPO to Fund Obesity Drugs
Mar 27, 21:43
Score 78
Bearish
Microsoft’s stock hasn’t been this oversold in a decade, with the tech giant ‘really losing the AI narrative’
Mar 27, 20:52
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.